SK-1403

DRUG2 trials

Sponsors

Sanwa Kagaku Kenkyusho Co., Ltd.

Conditions

Secondary Hyperparathyroidism

Phase 3

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

CompletedNCT03626948

Sanwa Kagaku Kenkyusho Co., Ltd.Secondary Hyperparathyroidism

Start: 2018-09-13End: 2020-02-05Updated: 2020-03-09

Phase 3 Study of SK-1403

CompletedNCT03801980

Sanwa Kagaku Kenkyusho Co., Ltd.Secondary Hyperparathyroidism

Start: 2019-01-21End: 2019-12-21Updated: 2020-03-09

Related Papers

Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism

Clinical Journal of the American Society of Nephrology2023-09-1120 citations